Generation of functional cardiomyocytes from mouse induced pluripotent stem cells

So, Kyoung Ha; Han, Young Joon; Park, Hyo Young; Kim, Jae Gon; Sung, Dong Jun; Bae, Young Min; Yang, Byoung‐Chul; Park, Soo Bong; Chang, Sang Keun; Kim, Eun Young; Park, Se Pill

doi:10.1016/j.ijcard.2010.08.052

Cited by 22 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20 Protocols mimicking conditions of embryonic cardiac development have been developed to boost the efficiency of cardiomyocyte generation from iPS cells. 21 These include 3-dimensional aggregates of pluripotent stem cells in suspension, known as embryoid bodies (EBs), 20,[22][23][24][25][26][27][28] monolayer differentiation combined with extracellular matrix with growth factors, 29 and inductive co-culture with mouse visceral endoderm-like cell line (END-2) 30,31 . iPS cells are therapeutically attractive given the lack of ethical or immune-rejection concerns.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: Improving the safety of iPS cell transplantation to myocardium

et al. 2014

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: Improving the safety of iPS cell transplantation to myocardium

et al. 2014

View full text Add to dashboard Cite

“…iPS cells can form embryoid-bodies with spontaneously contracting clusters [5] in the same way as ESCs. These contracting clusters have been shown to occur more readily with iPS cells than with ESCs, express cardiac mesoderm and cardiomyocyte markers and demonstrate electrophysiological properties [5].…”

Section: Induced Pluripotent Stem Cellsmentioning

confidence: 99%

“…These contracting clusters have been shown to occur more readily with iPS cells than with ESCs, express cardiac mesoderm and cardiomyocyte markers and demonstrate electrophysiological properties [5]. iPS cell-derived cardiomyocytes display a similar genetic profile to ESC-derived cardiomyocytes [71,72] and demonstrate similar contractile properties, although they are still significantly different in comparison to ventricular tissue of comparable age [73], demonstrating their immaturity.…”

Section: Induced Pluripotent Stem Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Stem Cell Therapy: A New Approach for Treatment of Myocardial Infarction

Faulkner¹,

Madeddu²

2012

J Stem Cell Res Ther

View full text Add to dashboard Cite

Stem cell therapy offers the opportunity of myocardial repair in patients who have suffered a myocardial infarction, a concept currently not feasible with present treatment options. Embryonic, adult, and induced pluripotent stem cells all offer a potential cell source for myocardial repair. Pre-clinical studies suggest that embryonic and induced pluripotent stem cells may be the most ideal cell type as they have the potential to differentiate into cardiomyocytes and restore a degree of functional recovery in animal models. Due to practical and ethical issues surrounding these cell types however, more focus has been on the use of adult stem cells, predominantly those of the bone-marrow. Pre-clinical studies suggest that bone-marrow stem cells can promote a degree of functional recovery through either differentiating into cardiomyocytes or acting in a paracrine manner to promote neoangiogenesis. The apparent success in pre-clinical models paved the way to a number of clinical trials to take place. Although mixed results have been reported, these trials have however shown that stem cell therapy is safe and feasible in humans. Many questions are still unanswered including, what is the optimal cell type, dose and timing of transplantation. This review highlights the benefits and limitations of each cell type and possible regenerative mechanisms.

show abstract

“…Embryonic stem cells (ESCs), adult stem cells (ASCs) and more recently induced pluripotent stem cells (iPS) all demonstrate the ability to differentiate into cardiaclineage cells in vitro (Xu et al, 2004;Caspi et al, 2007;So et al, 2010). As such, many research teams have focused on utilizing these cells as possible sources for myocardial repair in animal models of MI.…”

Section: Introductionmentioning

confidence: 99%

Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology

Jadczyk

Faulkner

Madeddu

2013

British J Pharmacology

View full text Add to dashboard Cite

Regenerative medicine holds great promise as a way of addressing the limitations of current treatments of ischaemic disease. In preclinical models, transplantation of different types of stem cells or progenitor cells results in improved recovery from ischaemia. Furthermore, experimental studies indicate that cell therapy influences a spectrum of processes, including neovascularization and cardiomyogenesis as well as inflammation, apoptosis and interstitial fibrosis. Thus, distinct strategies might be required for specific regenerative needs. Nonetheless, clinical studies have so far investigated a relatively small number of options, focusing mainly on the use of bone marrow-derived cells. Rapid clinical translation resulted in a number of small clinical trials that do not have sufficient power to address the therapeutic potential of the new approach. Moreover, full exploitation has been hindered so far by the absence of a solid theoretical framework and inadequate development plans. This article reviews the current knowledge on cell therapy and proposes a model theory for interpretation of experimental and clinical outcomes from a pharmacological perspective. Eventually, with an increased association between cell therapy and traditional pharmacotherapy, we will soon need to adopt a unified theory for understanding how the two practices additively interact for a patient's benefit. LINKED ARTICLESThis article is part of a themed section on Regenerative Medicine and Pharmacology: A Look to the Future. To view the other articles in this section visit http://dx

show abstract

Generation of functional cardiomyocytes from mouse induced pluripotent stem cells

Cited by 22 publications

References 24 publications

Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: Improving the safety of iPS cell transplantation to myocardium

Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: Improving the safety of iPS cell transplantation to myocardium

Stem Cell Therapy: A New Approach for Treatment of Myocardial Infarction

Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology

Contact Info

Product

Resources

About